ImmunoCellular Therapeutics Receives Notice of Allowance of Key U.S. Patent for Lead Product Candidate

LOS ANGELES--(BUSINESS WIRE)-- ImmunoCellular Therapeutics, Ltd. (OTCBB: IMUC) (“ImmunoCellular” or the “Company”), a biotechnology company focused on the development of novel immune-based cancer therapies, announced the allowance of U.S. patent claims related to ICT-107, the Company’s dendritic cell based cancer vaccine candidate targeting multiple tumor antigens for the treatment of glioblastoma multiforme (GBM). The Company received notice that a patent titled “Cancer Vaccines and Vaccination Methods,” which covers the method of delivery and the composition of the six antigens in ICT-107 that include TRP-2, MAGE-1, HER-2, IL-13 receptor a2, gp100 and AIM-2.

“The notice of allowance for this patent provides key support for the strong intellectual property protection we are building for ICT-107,” said John Yu, MD, one of the inventors of the patent and Chairman and Chief Scientific Officer of ImmunoCellular Therapeutics. “We continue to strengthen our intellectual property surrounding ICT-107 and other promising therapies.”

ImmunoCellular Therapeutics is currently conducting a Phase-II double-blind, placebo-controlled, 2:1 randomized study designed to evaluate the safety and efficacy of ICT-107 in patients with newly diagnosed GBM. The study will enroll approximately 160 patients at more than 20 clinical trial centers in the U.S. in collaboration with leading experts and opinion leaders in neuro-oncology.

The Phase I clinical study was conducted in 16 newly diagnosed glioblastoma patients, who received three injections of ICT-107 in addition to standard treatment with surgery, radiation and chemotherapy. The company has previously reported a three year overall survival of 55% compared to 16% based on historical standard of care (SOC). The data shows that 38% of newly diagnosed patients who received ICT-107 continue to show no tumor recurrence after three years compared to 6% disease free survival historically based on SOC. Out of these patients, 19% remain disease-free for more than four years. No serious adverse events have been reported and minor side effects have been limited to fatigue, skin rash and pruritis.

About ImmunoCellular Therapeutics, Ltd.

ImmunoCellular Therapeutics is a Los Angeles-based clinical-stage company that is developing immune-based therapies for the treatment of brain and other cancers. The Company recently commenced a Phase II trial of its lead product candidate, ICT-107, a dendritic cell-based vaccine targeting multiple tumor associated antigens for glioblastoma. To learn more about the Company, please visit www.imuc.com.

Forward-Looking Statements

This press release contains certain forward-looking statements that are subject to a number of risks and uncertainties, including the risk that patents issued covering ICT-107 may be challenged by third parties or may not provide commercially significant protection for that product and the risk that the safety and efficacy results obtained in the Phase I trial for ICT-107 will not be confirmed in subsequent trials. Additional risks and uncertainties are described in IMUC’s most recently filed SEC documents, such as its most recent annual report on Form 10-K, all quarterly reports on Form 10-Q and any current reports on Form 8-K. IMUC undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.



CONTACT:

For ImmunoCellular Therapeutics, Ltd.:
CEOcast, Inc.
James Young, (212) 732-4300
Investor Relations
[email protected]

KEYWORDS:   United States  North America  California

INDUSTRY KEYWORDS:   Health  Biotechnology  Clinical Trials  Oncology  Pharmaceutical

MEDIA:

Suggested Articles

Two weeks after receiving a second dose of Moderna's COVID-19 jab, patients had "robust" levels of neutralizing antibodies against the…

Despite questions about eye-related side effects, GlaxoSmithKline's anti-BCMA treatment emerged from an advisory committee meeting with a 12-0 vote.

After Mallinckrodt's terlipressin beat placebo at reversing kidney failure, an FDA panel will discuss the phase 3 trial's surrogate endpoint.